Penpulimab: Classification, Mechanism, Evidence and Pharmacovigilance

Penpulimab is an immune-checkpoint inhibitor directed against programmed cell death protein 1 (PD-1). Its pharmacovigilance profile therefore has to be understood at two levels: the product-specific evidence supporting its authorised indications and the broader biology of releasing PD-1-mediated immune restraint. The latter explains why adverse reactions may involve organs far removed from the tumour.

Classification, molecular design and regulatory context

Penpulimab is a humanised anti-PD-1 monoclonal antibody developed as AK105. Unlike the IgG4 backbone used by several PD-1 antibodies, penpulimab uses an engineered IgG1 Fc region designed to eliminate Fcγ-receptor binding and Fc-mediated effector functions. Published preclinical work reports that this Fc engineering reduces antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis and related Fc effects against PD-1-expressing immune cells.[4] These molecular features are biologically plausible differentiators, but claims that they produce superior clinical efficacy or safety over other PD-1 inhibitors require comparative clinical evidence and should not be inferred from engineering alone.

In the United States, FDA approved penpulimab-kcqx on 23 April 2025 for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in combination with cisplatin or carboplatin and gemcitabine in the first-line setting, and as monotherapy for metastatic non-keratinizing NPC progressing on or after platinum-based chemotherapy and at least one other prior line of therapy.[1,5] FDA's Purple Book records the product under BLA 761258 as a 351(a) biologic, 100 mg/10 mL intravenous injection, with first licensure on 23 April 2025.[6]

This scope matters. Evidence from other PD-1 inhibitors can help explain mechanism and class effects, but it does not enlarge penpulimab's authorised indication. Likewise, results from a combination regimen cannot automatically be attributed to penpulimab alone.

From AK105 to a multi-indication product

Penpulimab emerged from Akeso's antibody-development programme. Akeso describes the 2021 launch as the culmination of approximately nine years of development. In 2018, Akeso and Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical, entered a collaboration for subsequent development and commercialisation; the product was thereafter jointly developed through their collaboration.[7] In December 2021, Sino Biopharmaceutical announced an exclusive China sales arrangement under which it became the sole sales agent and assumed market-development, promotion and sales responsibilities.[8]

The first marketing approval came in China in August 2021 for adults with relapsed or refractory classical Hodgkin lymphoma after at least two prior lines of systemic chemotherapy. That approval followed a single-arm pivotal programme and preceded later approvals in squamous non-small-cell lung cancer and nasopharyngeal carcinoma.[7,9] By March 2025, China had approved a fourth indication—first-line recurrent or metastatic NPC in combination with chemotherapy—and in December 2025 a fifth Chinese indication was approved for penpulimab with anlotinib as first-line treatment of advanced hepatocellular carcinoma.[10,11]

The lifecycle is therefore geographically asymmetric. The current US label is focused on non-keratinizing NPC, whereas Chinese approvals span additional tumour types and combination regimens. Pharmacovigilance assessments must preserve jurisdiction, indication, regimen and date rather than treating “penpulimab use” as one homogeneous exposure.

Why PD-1 blockade changes both efficacy and safety

PD-1 is an inhibitory receptor expressed on activated immune cells. Engagement by its ligands can attenuate T-cell activity. Blocking this interaction can restore antitumour immune activity, but the same intervention can disturb peripheral immune tolerance.

For pharmacovigilance, this creates a characteristic causal problem. An event such as hepatitis, pneumonitis, colitis, thyroid dysfunction or nephritis may be immune-mediated, tumour-related, infectious, caused by chemotherapy, or multifactorial. Assessment therefore depends on timing, competing causes, investigations, response to treatment and the pattern of other immune manifestations rather than on event name alone.

Evidence supporting first-line combination use

FDA based the first-line combination approval on AK105-304, a randomised, double-blind trial of 291 patients with recurrent or metastatic NPC who had not received prior systemic chemotherapy for recurrent or metastatic disease. Patients received penpulimab or placebo with platinum and gemcitabine, followed by maintenance penpulimab or placebo.[1]

The phase 3 publication reported median progression-free survival of 9.63 months with penpulimab plus chemotherapy versus 7.00 months with placebo plus chemotherapy, with a hazard ratio of 0.45 (95% CI 0.33–0.62) at the prespecified interim analysis.[2] Overall-survival data were immature at that analysis. The distinction between a mature PFS result and immature OS evidence should be preserved when describing the benefit-risk evidence base.

Evidence beyond the US NPC programme

The broader development programme helps explain why post-authorisation evidence must be stratified by indication and regimen. China's initial classical Hodgkin lymphoma approval was supported by a single-arm study in which the independently reviewed objective response rate was 89.4% (76/85), with complete response in 47.1% (40/85) after a median follow-up of 15.8 months.[7] These response data supported the original Chinese regulatory decision but are not randomised comparative evidence.

In squamous NSCLC, the randomised phase 3 AK105-302 trial compared penpulimab plus paclitaxel/carboplatin with placebo plus the same chemotherapy. At the final analysis, median progression-free survival was 7.6 versus 4.2 months (HR 0.43, 95% CI 0.33–0.56); grade 3 or worse treatment-emergent adverse events occurred in 69% and 68%, respectively.[12] The near-similar high-grade overall event proportions illustrate why regimen-level adverse-event tables cannot be read as product-specific causality estimates.

Safety as a product and regimen question

In combination therapy, observed toxicity is the product of several exposures. Platinum compounds and gemcitabine can cause substantial haematological, renal, gastrointestinal and other toxicity, while PD-1 blockade introduces immune-mediated risks. The phase 3 publication reported grade 3 or higher treatment-related adverse events in both treatment groups, illustrating why raw adverse-event incidence cannot by itself establish which component caused an event.[2]

A useful case assessment separates three questions: what happened clinically; which mechanism best explains it; and which medicinal product or combination is the most plausible contributor. Laboratory trajectories, microbiology, imaging, concomitant medicines, chemotherapy-cycle timing, corticosteroid response and rechallenge information may materially alter causality.

Immune-mediated adverse reactions

Checkpoint inhibition can produce inflammatory injury in virtually any organ system. The US prescribing information warns that immune-mediated reactions may be severe or fatal, may involve any organ system, can affect more than one system simultaneously and can occur after treatment has stopped.[5] Clinically important patterns include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions and less common neurological, cardiac, ocular and haematological immune phenomena.

Product-specific frequencies should be kept separate from class statements. In the US safety dataset, immune-mediated hypothyroidism occurred in 16% of 146 patients receiving the NPC combination regimen and in 19% of 372 patients receiving penpulimab as a single agent; immune-mediated hepatitis occurred in 0.7% and 3.8%, respectively.[5] These denominators arise from defined clinical datasets and should not be converted into expected real-world incidence across all indications or jurisdictions.

Endocrine events deserve particular attention because the inflammatory phase may be transient while hormone deficiency persists. A report that records only "hypothyroidism" without thyroid tests, preceding hyperthyroid phase, symptoms, treatment and outcome loses information needed for medical assessment. The US label also calls for baseline and periodic evaluation of liver enzymes, creatinine and thyroid function and for investigation of alternative causes, including infection, when immune-mediated toxicity is suspected.[5]

Pharmacovigilance case assessment

For a suspected immune-mediated event, high-value follow-up includes onset relative to first and most recent doses; severity and objective findings; exclusion of infection and tumour progression; organ-specific investigations; corticosteroid or other immunosuppressive treatment; interruption or discontinuation; clinical and laboratory recovery; and any rechallenge outcome.

Combination treatment adds attribution complexity. Neutropenia temporally aligned with cytotoxic chemotherapy is a different causal problem from delayed inflammatory hepatitis after several treatment cycles. Both remain reportable when applicable, but signal interpretation should preserve their mechanistic differences.

Signal detection and aggregate review

Disproportionality or case counts alone cannot establish a new causal relationship. Review should consider clinical coherence, time-to-onset, dechallenge/rechallenge, dose and regimen, confounding, reporting geography, indication, concomitant chemotherapy and whether the event is already characterised for PD-1 blockade.

For a product with geographically evolving use, exposure context is especially important. Changes in reporting volume may reflect launch, new indications or stimulated reporting rather than a change in underlying risk.

Practical governance

The pharmacovigilance system should keep the current reference safety information, local labels and aggregate analyses aligned. Important differences between monotherapy and combination use should remain visible in case review and periodic evaluation. Medical review should also avoid importing the frequency or wording of an adverse reaction from another checkpoint inhibitor without product-specific evidence.

Traceability, regional labels and lifecycle surveillance

Penpulimab is a biological medicinal product, so product identification matters at case level. Useful reports should capture the medicinal-product name used locally, jurisdiction, indication, regimen, dose and administration dates and, where available, batch information. In the United States the proper name is penpulimab-kcqx; the four-letter suffix is part of the FDA-designated proper name and should not be silently discarded in US source documentation.[5,6]

Regional divergence also changes the background against which cases are interpreted. A hepatic event reported during penpulimab plus anlotinib for hepatocellular carcinoma in China is not equivalent to an event arising during US first-line NPC treatment with platinum/gemcitabine. Underlying liver disease, co-therapy and approved indication differ. Aggregate analyses should therefore stratify sufficiently to avoid creating an artificial pooled safety phenotype.

Lifecycle surveillance should also test claims made during development. Fc engineering is a genuine molecular characteristic, but whether it translates into clinically meaningful comparative safety remains an empirical question. Post-authorisation pharmacovigilance should not encode a presumed “lower immune-toxicity” profile as fact merely because that was a development hypothesis.

Inspection and quality perspective

An inspector evaluating checkpoint-inhibitor pharmacovigilance would be interested in whether serious immune-mediated cases are followed up to a medically useful standard, whether combination-therapy confounding is handled consistently, whether expectedness uses the correct reference safety information, and whether aggregate review can trace conclusions back to cases and exposure context.

A plausible failure mode is a medically important event being coded accurately but insufficiently characterised. Correct coding does not compensate for missing diagnostic work-up, treatment, outcome or competing-cause information. Another is treating a recognised class effect as automatically established for the product without evaluating product-specific evidence.

Key Takeaways

• Penpulimab is an Fc-engineered IgG1 PD-1-directed monoclonal antibody; molecular engineering should not be equated with proven comparative clinical superiority.
• Its first approval was in China in 2021 for relapsed/refractory classical Hodgkin lymphoma, followed by a broader Chinese indication lifecycle and US approval in 2025.
• US authorisation includes defined combination and monotherapy settings in non-keratinizing NPC.[1,5]
• The first-line NPC phase 3 evidence demonstrated a PFS benefit; OS was immature at the cited interim analysis.[2]
• Immune-mediated toxicity can occur across organs and after discontinuation, requiring active, organ-specific follow-up.[5]
• Combination therapy requires explicit separation of checkpoint-inhibitor, chemotherapy, disease and infection explanations.
• Jurisdiction, indication, regimen and biologic traceability should remain visible in case and aggregate assessment.
• Class knowledge informs assessment but does not replace product-specific regulatory information.

References

1. US Food and Drug Administration. FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma. 23 April 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma
2. Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study. PubMed PMID 41946687. https://pubmed.ncbi.nlm.nih.gov/41946687/
3. US Food and Drug Administration. Orphan Drug Designations and Approvals: penpulimab-kcqx. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=802020
4. Huang Z, Pang X, Zhong T, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022;13:924542. https://pubmed.ncbi.nlm.nih.gov/35833116/
5. US Food and Drug Administration. Penpulimab-kcqx prescribing information. BLA 761258. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761258s000lbl.pdf
6. US Food and Drug Administration. Purple Book: penpulimab-kcqx, BLA 761258. https://purplebooksearch.fda.gov/index.cfm?blaNo=761258&event=productdetails
7. Akeso. Penpulimab monoclonal antibody obtains marketing approval in China. 5 August 2021. https://www.akesobio.com/en/media/akeso-news/2021-8-5/
8. Sino Biopharmaceutical. Exclusive Sales Agreement of Penpulimab Monoclonal Antibody. 20 December 2021. https://www.sbpgroup.com/en/news-center/dynamic/24095.html
9. Dhillon S. Penpulimab: First Approval. Drugs. 2021. https://pubmed.ncbi.nlm.nih.gov/34813051/
10. Akeso. Penpulimab receives NMPA approval for first-line treatment of nasopharyngeal cancer. 17 March 2025. https://www.akesobio.com/en/media/akeso-news/20250317/
11. Sino Biopharmaceutical. Penpulimab with anlotinib approved for first-line advanced hepatocellular carcinoma. December 2025. https://www.en.sbpgroup.com/about/big-events/
12. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38309287/

Regulatory Note

This article distinguishes the FDA-authorised uses of penpulimab-kcqx from broader scientific discussion of PD-1 blockade. Regulatory status, product information and indications can change; current local prescribing information and applicable regulatory sources should be checked for operational decisions.